Subscribe to RSS
DOI: 10.1055/s-0039-1700562
Erratum to: Role of Pharmacologic Paralysis in Acute Respiratory Distress Syndrome
Publication History
Publication Date:
03 November 2019 (online)
![](https://www.thieme-connect.de/media/srccm/201901/lookinside/thumbnails/10-1055-s-0039-1700562_01443erratum-1.jpg)
Authors have informed the Publisher about an error in the above-mentioned article published in volume 40, issue 1 of the journal SRCCM. DOI of the original article: 10.1055/s-0039-1683883.
One randomized trial was inadvertently not included in this review. This trial, published in 2017, randomized 24 ARDS patients with a P/F < 150 and a PEEP ≥ 5 cm H2O, in two French ICUs, to a cisatracurium infusion for 48 hours or not (control group). All patients were monitored with an esophageal catheter and multiple respiratory mechanic and oxygenation metrics were measured over 48 hours. The authors found improved oxygenation, lower plateau pressure and total PEEP, and higher inspiratory and expiratory transpulmonary pressures, in the cisatracurium group versus the control group. The authors apologize for the omission.
Corrected table is as follows:
Trial |
N |
No. of hospitals |
Primary findings |
Year |
---|---|---|---|---|
Gainnier et al |
56 |
4 |
Improved oxygenation |
2004 |
Forel et al |
36 |
3 |
Decreased pulmonary and serum pro-inflammatory cytokine levels |
2006 |
ACURASYS |
340 |
20 |
Improved adjusted 90-d survival, with no difference in muscle weakness |
2010 |
Lyu et al |
96 |
1 |
Improved physiologic indices and 21-d survival, in severe ARDS |
2014 |
Guervilly et al |
24 |
2 |
Improved respiratory mechanics |
2017[a] |
ROSE |
1,006 |
48 |
Pending |
Enrollment completed 2018 |
Abbreviations: ACURASYS, ARDS et Curarisation Systematique; ARDS, acute respiratory distress syndrome; ROSE, Reevaluation Of Systemic Early neuromuscular blockade.
Note: Except for two trials, each trial randomized patients to cisatracurium for 48 hours versus placebo, and enrolled acute respiratory distress syndrome patients with a P/F < 150. (The Lyu et al trial tested vecuronium. The Forel et al and Lyu et al trials used a P/F < 200.)
a The reference for the 2017 trial is Guervilly C, et al. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Randomized controlled trial. Intensive Care Med 2017;43(3):408–418.